Novartis circles back with new terms for a stem cell biotech buyout–report – FierceBiotech
Globes |
Novartis circles back with new terms for a stem cell biotech buyout–report
FierceBiotech Novartis’ on-again, off-again deal to buy out Israeli stem cell therapy developer Gamida Cell is reportedly back on again–though the pharma giant has apparently renegotiated the old $600 million pact to include a smaller upfront buy-in and one of its … Novartis To Invest In Gamida Cell Before AcquistionNoCamels – Israeli Innovation News Novartis to Invest Heavily in Gamida CellJewish Business News |
Daily News & Analysis |
Stem cell study reveals how genetic variations linked to mental illness …
Daily News & Analysis A new study of stem cells has revealed how a genetic variation linked to schizophrenia, bipolar disorder and severe depression affects connections among neurons in the developing brain. According to the study led by Guo-li Ming and Hongjun Song of the … Stem cells reveal how illness-linked genetic variation affects neuronsEurekAlert (press release) Suspect gene corrupts neural connectionsScience Codex |
|
‘“Holy Grail’ of Stem Cell Biology can Cure Blood Disorders
Chinatopix Australian scientists have discovered mechanism that triggers Hematopoietic Stem Cell (HSC) production which can cure blood disorders and immune diseases. HSC can be found in the bone marrow and umbilical cord blood. It can replenish the blood cells … |
|
Stem cell patentability: European update following opinion of Advocate-General …
Lexology (registration) A recent Opinion of the Advocate-General of the Court of Justice of the European Union (CJEU)1 suggests that a clarification and moderation of the CJEU’s approach to the patentability of stem cells may be on the horizon. If followed, the law in Europe … |